Markets
Jensen Huang GTC 2026 San Jose
(Nvidia/YouTube)

Nvidia keeps giving Wall Street everything it wants — without getting rewarded

Yet another case of good financial news from Nvidia failing to generate an enduring positive reaction.

At Nvidia’s GPU Technology Conference, CEO Jensen Huang stressed that the chip designer could be everything to everyone in AI.

And that, along with a mammoth revenue outlook, was everything that Wall Street wanted to hear.

During his keynote, Huang repeatedly said that the chip designer is both vertically integrated (that is, offers all the solutions you need, not just GPUs) and also horizontally open (read: will integrate its offerings into whatever your technology stack happens to be). The headline, however, was his proclamation that AI chip sales would be at least $1 trillion through 2027.

Per analysts, Nvidia clarified that this $1 trillion guidance applies only to sales of Blackwell (which started shipping in its fiscal Q4 2025, roughly calendar Q4 2024) and Rubin chips, as well as associated networking equipment and CPUs, but not other products that were discussed at GTC. Therefore, the Street anticipates that overall data center sales are likely to come in well above that milestone figure.

Bottom line: no matter how you want to slice it, this number — and its implications for total revenues through calendar year 2027 — is an unmitigated thumbs-up relative to the consensus estimate.

But it’s yet another case of good financial news from Nvidia failing to generate an enduring positive reaction. Shares briefly spiked to session highs after Huang’s revenue guidance, but quickly lost all that advance and closed below where they were trading when the presentation started.

(That’s still better than the stock has done during most high-profile events recently.)

Here’s what analysts had to say about Huang’s keynote:

JPMorgan’s Harlan Sur, “overweight” rating, price target of $265:

“Net, while the market debate has shifted to AI spending cycle duration, we believe NVDA’s vertically integrated platform (now spanning seven chips, five rack systems, and the software stack to tie them together) is difficult to replicate, and the combination of accelerating inference demand, a structurally expanding TAM [total addressable market] via traditional workload acceleration, and a broadening customer base supports a more durable cycle than the market is currently underwriting.”

“NVDA’s Groq 3 LPU integration with Vera Rubin was the most architecturally significant product announcement — a disaggregated inference architecture that pairs Rubin GPUs (high throughput) with Groq LPUs (low latency decode) and positions NVDA to effectively service the low-latency inference market (where ASICs have traditionally held an advantage).”

Bernstein’s Stacy Rasgon, “outperform” rating, price target of $300:

“NVIDIA’s full platform approach appears increasingly difficult to disrupt as they relentlessly build out their software and hardware stacks across multiple offerings including GPUs, CPUs, DPUs, (now) LPUs, networking, and storage, and continue to drive token costs down by orders of magnitude with every generation which should allow them to capitalize as inference computing exponentiates; frankly we increasingly wonder how anyone else can compete with this.”

“NVIDIA’s roadmap looks really solid, their capability gap continues to widen, new offerings ought to help cement their position in inference just as they dominate training, and the order book suggests further upside to numbers, with the stock (in our opinion) almost absurdly valued given their positioning.”

Bank of America’s Vivek Arya, “buy” rating, price target of $300:

“1 gigawatt of data center now represents ~$40 billion of capex, with NVDA addressing $20-30 billion depending on networking content. Overall, we see continued NVDA leadership in AI backed by its broadening full-stack end-to-end pipeline, extreme co-design with customers, and supply assurance.”

Wedbush Securities’ Dan Ives, “outperform” rating, price target of $300:

“GTC 2026 was another opportunity for Jensen & Co. to further separate from the field in the AI arms race and they delivered, further reinforcing that Nvidia sits alone at the top of the AI mountain with the entire tech world watching below.”

“Inference has emerged as a dominant demand driver, with the GB200 NVL72 delivering up to 50x performance per watt and 35x lower cost per token compared to Hopper, making it the clear architecture of choice for enterprises scaling agentic AI workloads. With agentic systems now generating tokens at an exponential rate and the Groq licensing agreement set to unlock new levels of low-latency inference performance, the GB200 NVL72 sits at the center of the most important infrastructure buildout in the history of technology and NVDA’s inference leadership is only widening.”

Morgan Stanley’s Joseph Moore, “overweight” rating, price target of $260:

“We note that NVIDIA has consistently put up more upside to quarterly guidance than either of these competitors, and while just how strong 2027 is remains to be seen, we believe that NVIDIAs forecast leaves the most room for upside in the base case. Market share in this environment has more to do with supply chain, and we increasingly see potential for bottlenecks in other parts of the supply chain may actually bring preference to NVIDIA given a non supply limitation on GPU/XPU.

That’s especially relevant when the stock is trading at ~17x EPS [earnings-per-share] numbers that are likely to have material upside, discounting a falloff in earnings not yet in evidence. It’s certainly true that a semiconductor company’s views about demand 24 months into the future should be taken with a healthy dose of skepticism, but given bottlenecks in AI around land, power, and space, Nvidia’s customers are making planning decisions and commitments that far into the future, so it makes sense Nvidia is getting that visibility as well.”

More Markets

See all Markets
markets

Space, drone, and satellite stocks continue their Iran war-driven rally

Space, drone, and satellite stocks like Rocket Lab, Redwire, Intuitive Machines, AST SpaceMobile, and Planet Labs are outperforming both broader indexes and the thematic baskets of momentum stocks and shares with high retail sentiment with which they are often lumped.

There’s little clear news on the tape to attribute for the move higher. (Though the FAA did announce a streamlining of launch licensing rules that cover a number of these companies, including Rocket Lab and Firefly Aerospace, as well as Tesla CEO Elon Musk’s commercial space giant, SpaceX.)

More broadly, the outbreak of war with Iran has burnished the space, drone, and satellite sector in the eyes of investors, as the conflict underscores the importance of the three technologies to the future of defense. And in a world where nations are growing unsure of traditional alliances, countries across the board will look to boost their own capabilities. (Belgium just announced that it has selected Redwire, for example, to provide its first national security satellite system. Belgium!)

As Goldman Sachs analysts put it in a research note from January:

“Companies with native drone and satellite technology cultures like AeroVironment and Rocket Lab may find themselves particularly well positioned. And in Europe, a remilitarization of the Continent is underway that could require a $160bn investment over the next 5 years just to catch up with Russia.”

Since the start of the Iran war, most of these types of shares have handily outpaced the Nasdaq Composite Index. Rocket Lab, Redwire, and Intuitive Machines are all up more than 12% during that period, compared to a Nasdaq that’s just slightly in the red, as of shortly before 12 p.m. ET on Tuesday.

markets

Oklo surges after receiving approval for next phase in the construction of its first reactor

Revenue-free retail favorite Oklo is up in early trading after announcing regulatory updates on its first product, a reactor it calls Aurora, which it has started building at the US Energy Department’s primary nuclear energy research and development center, the Idaho National Laboratory.

Oklo announced that it signed an “other transaction agreement” (OTA) with the Department of Energy early Tuesday. (OTAs are typically used by the federal government to enter into research, prototyping, and production deals with private entities outside of the typical procurement processes.)

Oklo also announced that the DOE’s Idaho Operations Office also signed off on a preliminary safety design review for the reactor, which is expected to be completed sometime in late 2027 or 2028. The company broke ground on the project in September.

Separately, Oklo also announced that the Nuclear Regulatory Commission issued a materials license enabling an Oklo subsidiary to handle, process, and distribute isotopes.

“This is Oklo’s first NRC-issued license and supports the transition from design and planning to real-world execution and progress,” the company said.

Given the close involvement of the federal government in the development of nuclear power plants, Oklo’s close ties to the Trump administration have been seen as an important advantage for the company — but have also drawn scrutiny and criticism.

Energy Secretary Chris Wright was formerly a board member at Oklo, before he was tapped to lead the Trump administration’s Department of Energy.

The department is playing a more prominent role in the nuclear regulatory process under an executive order designed to speed up approval of new nuclear energy technologies.

Separately, Oklo is due to report earnings after the close of trading on Tuesday.

Oklo announced that it signed an “other transaction agreement” (OTA) with the Department of Energy early Tuesday. (OTAs are typically used by the federal government to enter into research, prototyping, and production deals with private entities outside of the typical procurement processes.)

Oklo also announced that the DOE’s Idaho Operations Office also signed off on a preliminary safety design review for the reactor, which is expected to be completed sometime in late 2027 or 2028. The company broke ground on the project in September.

Separately, Oklo also announced that the Nuclear Regulatory Commission issued a materials license enabling an Oklo subsidiary to handle, process, and distribute isotopes.

“This is Oklo’s first NRC-issued license and supports the transition from design and planning to real-world execution and progress,” the company said.

Given the close involvement of the federal government in the development of nuclear power plants, Oklo’s close ties to the Trump administration have been seen as an important advantage for the company — but have also drawn scrutiny and criticism.

Energy Secretary Chris Wright was formerly a board member at Oklo, before he was tapped to lead the Trump administration’s Department of Energy.

The department is playing a more prominent role in the nuclear regulatory process under an executive order designed to speed up approval of new nuclear energy technologies.

Separately, Oklo is due to report earnings after the close of trading on Tuesday.

markets

Eli Lilly receives its only sell rating as HSBC downgrades, citing smaller market for weight-loss drugs

Eli Lilly slipped in early trading after analysts at HSBC gave the pharmaceutical darling at the center of the obesity drug boom a rare downgrade.

Analysts at the bank cut their rating to “reduce” from “hold.” They cut their price target to $850 from $1,070. The stock closed at $989 on Monday.

“We think Lilly shares are priced to perfection, are uncomfortable with working capital trends, and think medium-term earnings trends are optimistic,” the analysts said.

According to Bloomberg, this is the only sell rating on Lilly among the 38 analysts who cover the stock.

The company has rallied more than 20% in the past year as its obesity drug sales continue to rise, far outpacing its top rival, Novo Nordisk.

But the space is getting increasingly crowded with new entrants and new products from Lilly and Novo, putting downward pricing pressure on their products. HSBC noted that the emergence of cash-pay channels for their drugs makes them subject to economic cycles and seasonality.

And while the introduction of oral options has expanded the market, HSBC analysts said they think “the compliance and persistence of these drugs might disappoint.”

“Whilst the momentum in the launch might be positive, we think oral drug launch expectations for Lilly are too high,” they said.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.